Skip to Content

Notice

Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee Meeting

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Assistant Secretary of Defense (Health Affairs), Department of Defense.

ACTION:

Notice of Federal Advisory Committee meeting.

SUMMARY:

The Department of Defense (DoD) is publishing this notice to announce that the following Federal Advisory Committee meeting of the Uniform Formulary Beneficiary Advisory Panel will take place.

DATES:

Open to the public Thursday, June 22, 2017 from 9:00 a.m. to 12:00 p.m.

ADDRESSES:

The address of the open meeting is Naval Heritage Center Theater, 701 Pennsylvania Avenue NW., Washington, DC 20004.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Edward Norton, 703-681-2890 (Voice), 703-681-1940 (Facsimile), dha.ncr.health-it.mbx.baprequests@mail.mil (Email). Mailing address is 7700 Arlington Boulevard, Suite 5101, Falls Church, VA 22042-5101. Web site: http://www.health.mil/​About-MHS/​Other-MHS-Organizations/​Beneficiary-Advisory-Panel. The most up-to-date changes to the meeting agenda can be found on the Web site.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

This meeting is being held under the provisions of the Federal Advisory Committee Act (FACA) of 1972 (5 U.S.C., Appendix, as amended), the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended), and 41 CFR 102-3.140 and 102-3.150.

Purpose of the Meeting: The Department of Defense is publishing this notice to announce a Federal Advisory Committee meeting of the Uniform Formulary Beneficiary Advisory Panel (hereafter referred to as the Panel).

Agenda:

1. Sign-In.

2. Welcome and Opening Remarks.

3. Public Citizen Comments.

4. Scheduled Therapeutic Class Reviews (Comments will follow each agenda item).

a. Ophthalmic-1 Agents.

b. Pulmonary Miscellaneous.

5. Newly Approved Drugs Review.

6. Pertinent Utilization Management Issues.

7. Panel Discussions and Vote.

Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 41 Code of Federal Regulations (CFR) 102-3.140 through 102-3.165, and the availability of space, this meeting is open to the public. Seating is limited and will be provided only to the first 220 people signing-in. All persons must sign-in legibly.

Written Statements: Pursuant to 41 CFR 102-3.140, the public or interested organizations may submit written statements to the membership of the Panel at any time or in response to the stated agenda of a planned meeting. Written statements should be submitted to the Panel's Designated Federal Officer (DFO). The DFO's contact information can be obtained from the General Services Administration's Federal Advisory Committee Act Database at http://facadatabase.gov/​. Written statements that do not pertain to the scheduled meeting of the Panel may be submitted at any time. However, if individual comments pertain to a specific topic being discussed at a planned meeting, then these statements must be submitted no later than 5 business days prior to the meeting in question. The DFO will review all submitted written statements and provide copies to all the committee members.

Public Comments: In addition to written statements, the Panel will set aside 1 hour for individuals or interested groups to address the Panel. To ensure consideration of their comments, individuals and interested groups should submit written statements as outlined in this notice; but if they still want to address the Panel, then they will be afforded the opportunity to register to address the Panel. The Panel's DFO will have a “Sign-Up Roster” available at the Panel meeting for registration on a first-come, first-serve basis. Those wishing to address the Panel will be given no more than 5 minutes to present their comments, and at the end of the 1-hour time period, no further public comments will be accepted. Anyone who signs-up to address the Panel, but is unable to do so due to the time limitation, may submit their comments in writing; however, they must understand that their written comments may not be reviewed prior to the Panel's deliberation. To ensure timeliness of comments for the official record, the Panel encourages that individuals and interested groups consider submitting written statements instead of addressing the Panel.

Start Signature

Dated: May 5, 2017.

Aaron Siegel,

Alternate OSD Federal Register Liaison Officer, Department of Defense.

End Signature End Supplemental Information

[FR Doc. 2017-09450 Filed 5-9-17; 8:45 am]

BILLING CODE 5001-06-P